Drug facts News & Updates

FDA warns severe joint pain may be caused by Gliptins – DPP-4 inhibitors

DPP-4 inhibitors used to treat type 2 diabetes, this class includes different brands in single molecule or combined with other molecules like metformin.

DPP-4 inhibitors brands:

 Brand name Active ingredient(s)
Januviasitagliptin
Janumetsitagliptin and metformin
Janumet XRsitagliptin and metformin extended release
Onglyzasaxagliptin
Kombiglyze XRsaxagliptin and metformin extended release
Tradjentalinagliptin
Glyxambilinagliptin and empagliflozin
Jentaduetolinagliptin and metformin
Nesinaalogliptin
Kazanoalogliptin and metformin
Osenialogliptin and pioglitazone

According to FDA, 33 cases of severe arthralgia have been reported with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors from October 16, 2006, approval date of the first DPP-4 inhibitor, through December 31, 2013.

Sitagliptin was the most frequently reported with 28 cases , followed by saxagliptin 5 cases , linagliptin 2 cases , alogliptin only 1 case and vildagliptin two cases.

Although the number of reported cases is very low compared to the patients who use DPP-4 inhibitors, you should report any severe joint pain or any other related symptoms to your health care professional.

To download the full FDA safety warning please follow this link :

http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf

 

 

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x